In the context of cancer, in a KRAS-mutant lung cancer patient-derived xenograft model, coupling of a mitogen-activated protein kinase inhibitor and a pro-senescence CDK4/6 inhibitor, impaired tumour growth to a greater extent than either drug alone92. This evidence concerns the gene KRAS and lung carcinoma.